MiNK Therapeutics reports Q1 net loss of $2.8M; cash burn down; clinical progress in iNKT platform

MiNK Therapeutics, Inc.

2025-Q1 EPS reported -$0.70

Net loss of $2.8M ($0.70/sh) vs $3.8M ($1.10/sh) YoY; cash used in ops down to $1.3M from $2.5M.
Cash balance of $3.2M at March 31, 2025; company pursuing near-term capital transactions to bolster liquidity.
Phase 2 gastric trial (NCT06251973) enrolling; new data shows agenT-797 activity in PD-1-resistant gastroesophageal cancers.
Complete remission in metastatic testicular cancer after single agenT-797 infusion without lymphodepletion or toxicity.
Selected for probable NIAID funding for GvHD program; strategic discussions underway across oncology and immunology.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.